These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 23238158)

  • 1. Genomic mapping and survival prediction in glioblastoma: molecular subclassification strengthened by hemodynamic imaging biomarkers.
    Jain R; Poisson L; Narang J; Gutman D; Scarpace L; Hwang SN; Holder C; Wintermark M; Colen RR; Kirby J; Freymann J; Brat DJ; Jaffe C; Mikkelsen T
    Radiology; 2013 Apr; 267(1):212-20. PubMed ID: 23238158
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcome prediction in patients with glioblastoma by using imaging, clinical, and genomic biomarkers: focus on the nonenhancing component of the tumor.
    Jain R; Poisson LM; Gutman D; Scarpace L; Hwang SN; Holder CA; Wintermark M; Rao A; Colen RR; Kirby J; Freymann J; Jaffe CC; Mikkelsen T; Flanders A
    Radiology; 2014 Aug; 272(2):484-93. PubMed ID: 24646147
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiparametric MR Imaging of Diffusion and Perfusion in Contrast-enhancing and Nonenhancing Components in Patients with Glioblastoma.
    Boonzaier NR; Larkin TJ; Matys T; van der Hoorn A; Yan JL; Price SJ
    Radiology; 2017 Jul; 284(1):180-190. PubMed ID: 28240563
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glioblastoma: a method for predicting response to antiangiogenic chemotherapy by using MR perfusion imaging--pilot study.
    Sawlani RN; Raizer J; Horowitz SW; Shin W; Grimm SA; Chandler JP; Levy R; Getch C; Carroll TJ
    Radiology; 2010 May; 255(2):622-8. PubMed ID: 20413772
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pseudoprogression of glioblastoma after chemo- and radiation therapy: diagnosis by using dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging with ferumoxytol versus gadoteridol and correlation with survival.
    Gahramanov S; Muldoon LL; Varallyay CG; Li X; Kraemer DF; Fu R; Hamilton BE; Rooney WD; Neuwelt EA
    Radiology; 2013 Mar; 266(3):842-52. PubMed ID: 23204544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of survival in patients affected by glioblastoma: histogram analysis of perfusion MRI.
    Romano A; Pasquini L; Di Napoli A; Tavanti F; Boellis A; Rossi Espagnet MC; Minniti G; Bozzao A
    J Neurooncol; 2018 Sep; 139(2):455-460. PubMed ID: 29721752
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Voxel-based evidence of perfusion normalization in glioblastoma patients included in a phase I-II trial of radiotherapy/tipifarnib combination.
    Ken S; Deviers A; Filleron T; Catalaa I; Lotterie JA; Khalifa J; Lubrano V; Berry I; Péran P; Celsis P; Moyal EC; Laprie A
    J Neurooncol; 2015 Sep; 124(3):465-73. PubMed ID: 26189058
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pretreatment Dynamic Susceptibility Contrast MRI Perfusion in Glioblastoma: Prediction of EGFR Gene Amplification.
    Gupta A; Young RJ; Shah AD; Schweitzer AD; Graber JJ; Shi W; Zhang Z; Huse J; Omuro AM
    Clin Neuroradiol; 2015 Jun; 25(2):143-50. PubMed ID: 24474262
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The preliminary radiogenomics association between MR perfusion imaging parameters and genomic biomarkers, and their predictive performance of overall survival in patients with glioblastoma.
    Liu X; Mangla R; Tian W; Qiu X; Li D; Walter KA; Ekholm S; Johnson MD
    J Neurooncol; 2017 Dec; 135(3):553-560. PubMed ID: 28889246
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of dynamic susceptibility-weighted contrast-enhanced MR methods: recommendations for measuring relative cerebral blood volume in brain tumors.
    Paulson ES; Schmainda KM
    Radiology; 2008 Nov; 249(2):601-13. PubMed ID: 18780827
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation of relative permeability and relative cerebral blood volume in high-grade cerebral neoplasms.
    Provenzale JM; York G; Moya MG; Parks L; Choma M; Kealey S; Cole P; Serajuddin H
    AJR Am J Roentgenol; 2006 Oct; 187(4):1036-42. PubMed ID: 16985154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relative cerebral blood volume is a potential predictive imaging biomarker of bevacizumab efficacy in recurrent glioblastoma.
    Kickingereder P; Wiestler B; Burth S; Wick A; Nowosielski M; Heiland S; Schlemmer HP; Wick W; Bendszus M; Radbruch A
    Neuro Oncol; 2015 Aug; 17(8):1139-47. PubMed ID: 25754089
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival analysis in patients with newly diagnosed primary glioblastoma multiforme using pre- and post-treatment peritumoral perfusion imaging parameters.
    Bag AK; Cezayirli PC; Davenport JJ; Gaddikeri S; Fathallah-Shaykh HM; Cantor A; Han XS; Nabors LB
    J Neurooncol; 2014 Nov; 120(2):361-70. PubMed ID: 25098699
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved perfusion MR imaging assessment of intracerebral tumor blood volume and antiangiogenic therapy efficacy in a rat model with ferumoxytol.
    Gahramanov S; Muldoon LL; Li X; Neuwelt EA
    Radiology; 2011 Dec; 261(3):796-804. PubMed ID: 21940504
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cerebral blood volume measurements by perfusion-weighted MR imaging in gliomas: ready for prime time in predicting short-term outcome and recurrent disease?
    Bisdas S; Kirkpatrick M; Giglio P; Welsh C; Spampinato MV; Rumboldt Z
    AJNR Am J Neuroradiol; 2009 Apr; 30(4):681-8. PubMed ID: 19179427
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dynamic susceptibility contrast MRI measures of relative cerebral blood volume as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 multicenter trial.
    Schmainda KM; Zhang Z; Prah M; Snyder BS; Gilbert MR; Sorensen AG; Barboriak DP; Boxerman JL
    Neuro Oncol; 2015 Aug; 17(8):1148-56. PubMed ID: 25646027
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined analysis of MGMT methylation and dynamic-susceptibility-contrast MRI for the distinction between early and pseudo-progression in glioblastoma patients.
    Bani-Sadr A; Berner LP; Barritault M; Chamard L; Bidet CM; Eker OF; Hermier M; Guyotat J; Jouanneau E; Meyronet D; Gouttard S; D'Hombres A; Iziquierdo C; Honnorat J; Berthezène Y; Ducray F
    Rev Neurol (Paris); 2019 Oct; 175(9):534-543. PubMed ID: 31208813
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MR imaging predictors of molecular profile and survival: multi-institutional study of the TCGA glioblastoma data set.
    Gutman DA; Cooper LA; Hwang SN; Holder CA; Gao J; Aurora TD; Dunn WD; Scarpace L; Mikkelsen T; Jain R; Wintermark M; Jilwan M; Raghavan P; Huang E; Clifford RJ; Mongkolwat P; Kleper V; Freymann J; Kirby J; Zinn PO; Moreno CS; Jaffe C; Colen R; Rubin DL; Saltz J; Flanders A; Brat DJ
    Radiology; 2013 May; 267(2):560-9. PubMed ID: 23392431
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential for differentiation of pseudoprogression from true tumor progression with dynamic susceptibility-weighted contrast-enhanced magnetic resonance imaging using ferumoxytol vs. gadoteridol: a pilot study.
    Gahramanov S; Raslan AM; Muldoon LL; Hamilton BE; Rooney WD; Varallyay CG; Njus JM; Haluska M; Neuwelt EA
    Int J Radiat Oncol Biol Phys; 2011 Feb; 79(2):514-23. PubMed ID: 20395065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glial tumor grading and outcome prediction using dynamic spin-echo MR susceptibility mapping compared with conventional contrast-enhanced MR: confounding effect of elevated rCBV of oligodendrogliomas [corrected].
    Lev MH; Ozsunar Y; Henson JW; Rasheed AA; Barest GD; Harsh GR; Fitzek MM; Chiocca EA; Rabinov JD; Csavoy AN; Rosen BR; Hochberg FH; Schaefer PW; Gonzalez RG
    AJNR Am J Neuroradiol; 2004 Feb; 25(2):214-21. PubMed ID: 14970020
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.